BAX Baxter International, Inc.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Company profile
Ticker
BAX
Exchange
Website
CEO
José E. Almeida
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Becton Dickinson & Co • 3M • Teleflex • ResMed • Hill-Rom • Boston Scientific • Integra Lifesciences • Haemonetics • NuVasive • Merit Medical Systems ...
SEC CIK
Corporate docs
IRS number
360781620
Calendar
17 Mar 20
2 Apr 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | 3.04B | 2.85B | 2.83B | 2.64B | |
| Net income | -23M | 369M | 313M | 342M | |
| Diluted EPS | -0.05 | 0.71 | 0.6 | 0.66 | |
| Net profit margin | -0.76% | 12.94% | 11.04% | 12.96% | |
| Operating income | 536M | 503M | 350M | 383M | |
| Net change in cash | 326M | 75M | 1.03B | 64M | |
| Cash on hand | 3.34B | 3.01B | 2.93B | 1.9B | |
| Cost of revenue | 1.74B | 1.62B | 1.68B | 1.56B |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 11.36B | 11.1B | 10.56B | 10.16B | |
| Net income | 1B | 1.55B | 602M | 4.97B | |
| Diluted EPS | 1.93 | 2.83 | 1.08 | 9.01 | |
| Net profit margin | 8.81% | 13.93% | 5.70% | 48.85% | |
| Operating income | 1.77B | 1.58B | 1.29B | 745M | |
| Net change in cash | 1.5B | -1.56B | 593M | 588M | |
| Cash on hand | 3.34B | 1.84B | 3.39B | 2.8B | |
| Cost of revenue | 6.6B | 6.34B | 6.11B | 6.05B |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|
| 30 Mar 20 | Martin Sean | Common Stock, $1 par value | Buy | Aquire P | 82.19 | 9,780 | 803.82K | 39,504 |
| 20 Mar 20 | Frye Andrew | Stock Option Common Stock, $1 par value | Grant | Aquire A | 75.75 | 57,216 | 4.33M | 57,216 |
| 20 Mar 20 | Franzi Cristiano | Stock Option Common Stock, $1 par value | Grant | Aquire A | 75.75 | 63,573 | 4.82M | 63,573 |
| 20 Mar 20 | Stevens Brian | Common Stock, $1 par value | Grant | Aquire A | 0 | 1,579 | 0 | 17,908 |
| 20 Mar 20 | Stevens Brian | Stock Option Common Stock, $1 par value | Grant | Aquire A | 75.75 | 15,893 | 1.2M | 15,893 |
Institutional ownership Q4 2019
83.7% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1115 |
| Opened positions | 144 |
| Closed positions | 97 |
| Increased positions | 336 |
| Reduced positions | 410 |
13F shares |
Current |
|---|---|
| Total value | 35.5B |
| Total shares | 424.43M |
| Total puts | 1.43M |
| Total calls | 2.52M |
| Total put/call ratio | 0.6 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK BlackRock | 40.8M | $3.41B |
| Vanguard | 39.3M | $3.29B |
| Wellington Management | 31.23M | $2.61B |
| STT State Street | 23.87M | $2B |
| MS Morgan Stanley | 18.03M | $1.51B |
| Third Point | 17.5M | $1.46B |
| FMR | 13.49M | $1.13B |
| AMP Ameriprise Financial | 10.42M | $871.14M |
| NTRS Northern Trust | 8.67M | $725.25M |
| Veritas Asset Management | 7.26M | $607.39M |
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abdominal, adjunct, AdvaMed, Advisory, aforementioned, African, air, al, alleged, allegedly, alleging, American, Amy, annuity, annum, appointed, avoid, avoiding, background, Barrier, bladder, bowel, Brian, brought, bundled, burden, captured, Cathy, CCPA, certify, Chapter, Cheetah, Cherry, Codification, Commissioner, comparison, condensed, configured, contaminant, convention, Council, County, cure, cylophosphamide, daily, declaratory, dedesignated, deficiency, deployment, dialyzer, disaggregate, disbursed, disgorgement, distinguish, Donald, Eleventh, emission, Ethan, ethylene, Eucomed, eventual, EVO, exacerbate, Explanatory, factor, Family, Fayette, feed, fiduciary, filer, Gandhinagar, Georgia, Guarantor, Guaranty, Gujarat, hamper, hemodynamic, heparin, Hill, HIPAA, improperly, inactive, incorrect, incorrectly, Indian, internet, investor, involuntary, IQ, Jacqueline, knowledge, Kunzler, lack, laparotomy, lawsuit, led, Lira, longstanding, Louisiana, main, manual, MDL, meantime, misclassification, misleading, Morrison, Mountain, necessitating, NJ, Ohio, omentum, opiate, opioid, orally, overlap, overstated, oxide, Patricia, pelvic, persist, Police, postoperative, PrisMax, professional, prolonged, promulgated, proportion, Prudential, publicly, punitive, quantification, rapid, recommenced, reconcile, reconciling, recovery, regain, regained, remitted, sample, Sanofi, Seprafilm, shelf, shorten, Show, Silverman, sixty, skill, Smith, speculate, stomach, strive, thirty, timeframe, travel, Trump, Twelfth, uncorrected, unknown, unlock, unspecified, Varma, viscera, Waiver, wall, Wendell
Removed:
accelerate, Accountant, achieving, ApaTech, awaiting, bench, beneficiary, bet, BioPharma, bone, Branch, Branded, breakage, Brik, bringing, cancelable, cancelling, carried, Catano, categorized, claim, COLLEAGUE, Colorado, comparative, coupon, davita, discontinuance, discontinuation, divided, effected, exchanged, expiring, extinguishment, Eyre, Fee, Gambro, German, grouping, ICOA, inflow, initiated, intercompany, joining, long, matured, maximizing, medicine, Mine, nonstrategic, occurring, outflow, paper, placement, Pleau, postemployment, predominantly, premium, prepayment, PreSource, prevailed, reassign, redeem, redeemed, redemption, referendum, refund, repayment, requiring, RP, Scott, sector, settling, simplifying, substitute, suit, supplied, swap, synthetic, systematically, tender, trial, unexpected, unpaid, unremitted, Unresolved, vancomycin, viability, VIVIA, warranty, workforce
Financial reports
10-K
2019 FY
Annual report
17 Mar 20
10-Q
2019 Q3
Quarterly report
17 Mar 20
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
21 Feb 19
10-Q
2018 Q3
Quarterly report
5 Nov 18
10-Q
2018 Q2
Quarterly report
6 Aug 18
10-Q
2018 Q1
Quarterly report
9 May 18
10-K
2017 FY
Annual report
23 Feb 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
Current reports
8-K
Entry into a Material Definitive Agreement
27 Mar 20
8-K
Regulation FD Disclosure
23 Mar 20
8-K
Completes Financial Restatement Process
17 Mar 20
8-K
Other Events
25 Feb 20
8-K
Results of Operations and Financial Condition
13 Feb 20
8-K
Baxter Announces Preliminary Net Sales for the Fourth-quarter and Full-year 2019 and Announces Preliminary Full-year 2020 Guidance
13 Jan 20
8-K
Entry into a Material Definitive Agreement
20 Dec 19
8-K
Baxter Receives Nyse Notice Regarding Delayed FORM10-Q Filing
22 Nov 19
8-K
Other Events
6 Nov 19
8-K
Other Events
28 Oct 19
Registration and prospectus
8-A12B
Registration of securities on exchange
15 May 19
424B2
Prospectus for primary offering
14 May 19
FWP
Free writing prospectus
10 May 19
424B5
Prospectus supplement for primary offering
10 May 19
S-3ASR
Automatic shelf registration
23 Aug 18
8-A12B
Registration of securities on exchange
30 May 17
424B2
Prospectus for primary offering
22 May 17
424B5
Prospectus supplement for primary offering
19 May 17
FWP
Free writing prospectus
19 May 17
424B5
Prospectus supplement for primary offering
12 Aug 16
Proxies
DEFA14A
Additional proxy soliciting materials
31 Mar 20
DEFA14A
Additional proxy soliciting materials
17 Mar 20
DEF 14A
Definitive proxy
17 Mar 20
DEFA14A
Additional proxy soliciting materials
26 Mar 19
DEF 14A
Definitive proxy
26 Mar 19
DEF 14A
Definitive proxy
23 Mar 18
DEFA14A
Additional proxy soliciting materials
23 Mar 18
DEF 14A
Definitive proxy
17 Mar 17
DEFA14A
Additional proxy soliciting materials
17 Mar 17
DEF 14A
Definitive proxy
24 Mar 16
Other
SD
Conflict minerals disclosure
24 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
30 May 17
UPLOAD
Letter from SEC
10 May 17
CORRESP
Correspondence with SEC
28 Apr 17
CORRESP
Correspondence with SEC
14 Apr 17
UPLOAD
Letter from SEC
31 Mar 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Ownership
4
BAXTER INTERNATIONAL / Sean Martin ownership change
1 Apr 20
3
BAXTER INTERNATIONAL / Alex N Blanco ownership change
1 Apr 20
4
BAXTER INTERNATIONAL / Brian Stevens ownership change
23 Mar 20
4
BAXTER INTERNATIONAL / JAMES SACCARO ownership change
23 Mar 20
4
BAXTER INTERNATIONAL / Jeanne K Mason ownership change
23 Mar 20
4
BAXTER INTERNATIONAL / Sean Martin ownership change
23 Mar 20
4
BAXTER INTERNATIONAL / Jacqueline Kunzler ownership change
23 Mar 20
4
BAXTER INTERNATIONAL / Andrew Frye ownership change
23 Mar 20
4
BAXTER INTERNATIONAL / Cristiano Franzi ownership change
23 Mar 20
4
BAXTER INTERNATIONAL / JOSE E ALMEIDA ownership change
23 Mar 20
Patents
GRANT
Utility
Dialysis monitors and methods of operation
31 Mar 20
Dialysis monitors capable of storing and using thermal energy and methods related thereto are disclosed.
GRANT
Utility
Systems for performing peritoneal dialysis using vacuum source and weight sensor
31 Mar 20
A peritoneal dialysis system includes: a drain container; a drain line placed in fluid communication with the drain container and configured to be placed in fluid communication with a patient's peritoneal cavity; a vacuum source configured to apply a pneumatic force to cause used dialysis fluid to flow through the drain line from the patient's peritoneal cavity to the drain container; a weight sensor configured to output a weight of used dialysis fluid delivered to the drain container from the patient's peritoneal cavity; and a controller configured to: (i) determine an actual flow rate of used dialysis fluid removed from the patient's peritoneal cavity based on the output from the weight sensor; (ii) compare the actual flow rate to a desired flow rate; and (iii) adjust the pneumatic force applied by the vacuum source to attempt to match the actual flow rate to the optimal flow rate.
APP
Utility
Synthetic Tissue Glue
19 Mar 20
Compositions for use as a tissue glue or sealant are disclosed.
APP
Utility
Peritoneal Dialysis Patient Line with Sterilizing Filter and Drain Bypass
19 Mar 20
A medical fluid treatment system includes a source of purified water; at least one concentrate for mixing with the water from the source to form a treatment fluid; a disposable set including a pumping portion, a concentrate line in fluid communication with the concentrate source and the pumping portion, and a patient line in fluid communication with the pumping portion, the patient line including a filter having a membrane configured to filter the treatment fluid, the filter configured such that (i) fresh treatment fluid flowing from the pumping portion towards a patient flows through the membrane and (ii) used treatment fluid flowing through the filter from the patient to the pumping portion bypasses the membrane; and a medical fluid delivery machine including a pump actuator operable with the pumping portion of the disposable set.
APP
Utility
Low Swelling Synthetic Sealant
19 Mar 20
Compositions for use as a low-swelling tissue sealant are disclosed.